Myomo, Inc.
AMEX:MYOMedical - Devices
-$0.13 today
- Market cap
- $50.12M
- Beta
- 1.46
- P/E (TTM)
- -3.6
- EPS (TTM)
- -$0.36
Volume 0.21M
Average 0.62M
MYO Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
Myomo, Inc.AMEX: MYO
Research & Development · Q1 FY2026 · quarter ended Mar 2026
Research & development dips below year-ago levels
Q1 FY2026 research & development of $1.62M fell 9.3% year over year, behind the +20.9% change in trailing-twelve-month research & development. Sequentially, it fell 0.1% from the prior quarter. Over 3 fiscal years it compounded at +40.9% a year.
Context
- Research & development amounted to 17.0% of revenue in FY2025, up 2.3 pp from a year earlier.
- Research & development increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from -9.3% toward the trailing-twelve-month pace of +20.9%.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
USD · from the income statement
- Latest · FY2025
- 6.94M USD
- Year-over-year change
- +45.5%
- 4-year CAGR
- +28.4%
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 6.94M | +45.5% |
| FY2024 | 2024-12-31 | 4.77M | +81.0% |
| FY2023 | 2023-12-31 | 2.64M | +6.2% |
| FY2022 | 2022-12-31 | 2.48M | -2.9% |
| FY2021 | 2021-12-31 | 2.56M | — |
Research & Development vs competitors
How MYO compares with its peers on the latest reported figures
- MYO's LTM Mar 2026 research & development of $6.78M is the highest of the 4 companies compared; the peer median is $1.06M.
- Its year-over-year change of +20.9% is the highest of 4, against a peer median of -17.7%.
- Research & development amounts to 16.4% of revenue for MYO, versus a peer median of 8.1%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $6.78M | +20.9% | +40.9% | 16.4% | |
| LTM Mar 2026 | $2.83M | +8.8% | -20.9% | 8.1% | |
| LTM Mar 2026 | $1.06M | -17.7% | +20.2% | 3.7% | |
| LTM Jun 2026 | $908.07K | -86.6% | -47.7% | 64.8% | |
| Peer median (excluding MYO) | $1.06M | -17.7% | -20.9% | 8.1% | |
Competitors are the stored peer set for MYO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 13.86M | 15.56M | 19.24M | 32.55M | 40.93M |
| Cost of Revenue | 3.54M | 5.3M | 6.06M | 9.37M | 14.04M |
| Gross Profit | 10.31M | 10.25M | 13.18M | 23.19M | 26.89M |
| Gross Margin | 74.4% | 65.9% | 68.5% | 71.2% | 65.7% |
| Research & Development | 2.56M | 2.48M | 2.64M | 4.77M | 6.94M |
| Selling, General & Admin | 18.02M | 18.44M | 18.78M | 24.62M | 34.35M |
| Operating Expenses | 20.58M | 20.93M | 21.41M | 29.39M | 41.29M |
| Depreciation & Amortization | 335.96K | 542.63K | 517.68K | 776.97K | 1.76M |
| EBITDA | (9.95M) | (10.11M) | (7.47M) | (5.04M) | (12.38M) |
| EBITDA Margin | -71.8% | -65.0% | -38.8% | -15.5% | -30.2% |
| Operating Income | (10.27M) | (10.67M) | (8.23M) | (6.21M) | (14.4M) |
| Operating Margin | -74.1% | -68.6% | -42.8% | -19.1% | -35.2% |
| Interest Income | 1.61K | 88.73K | 410.27K | 388.59K | 476.97K |
| Interest Expense | 0 | 0 | 0 | 0 | 927.8K |
| Other Income / Expenses | (15.34K) | 21.12K | 239.99K | 388.59K | (667.51K) |
| Income Before Tax | (10.28M) | (10.65M) | (7.99M) | (5.82M) | (15.07M) |
| Pre-Tax Margin | -74.2% | -68.5% | -41.5% | -17.9% | -36.8% |
| Income Tax Expense | 88.93K | 69.94K | 156K | 365.62K | 504.53K |
| Net Income | (10.37M) | (10.72M) | (8.15M) | (6.18M) | (15.57M) |
| Net Margin | -74.9% | -68.9% | -42.3% | -19.0% | -38.1% |
| EPS (Basic) | (1.78) | (1.52) | (0.28) | (0.16) | (0.37) |
| EPS (Diluted) | (1.78) | (1.52) | (0.28) | (0.16) | (0.37) |
| Weighted Avg Shares | 5.83M | 7.05M | 29.1M | 37.76M | 41.86M |
| Weighted Avg Shares (Diluted) | 5.83M | 7.05M | 29.5M | 37.76M | 41.86M |
Myomo, Inc.
AMEX:MYO
Intrinsic Alpha fair value
Locked
Current Price
$1.25
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.